Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $412,356.93 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 13,551 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $412,356.93. Following the completion of the transaction, the chief executive officer now owns 418,519 shares of the company’s stock, valued at $12,735,533.17. This represents a 3.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Cedric Francois also recently made the following trade(s):

• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Stock Down 2.5 %

NASDAQ APLS opened at $30.00 on Friday. The business has a fifty day moving average price of $32.08 and a 200 day moving average price of $33.15. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $71.90. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The company has a market cap of $3.73 billion, a P/E ratio of -14.78 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same period last year, the business earned ($1.17) earnings per share. The firm’s revenue was up 78.3% compared to the same quarter last year. Research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on APLS. HC Wainwright reiterated a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Scotiabank dropped their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler dropped their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Morgan Stanley began coverage on Apellis Pharmaceuticals in a research report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Finally, Robert W. Baird dropped their target price on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Institutional Trading of Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of APLS. JPMorgan Chase & Co. grew its holdings in shares of Apellis Pharmaceuticals by 23.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after purchasing an additional 735,160 shares during the period. Braidwell LP grew its holdings in shares of Apellis Pharmaceuticals by 410.8% during the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after purchasing an additional 2,513,383 shares during the period. Jennison Associates LLC grew its holdings in shares of Apellis Pharmaceuticals by 51.6% during the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after purchasing an additional 939,289 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Apellis Pharmaceuticals by 191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after purchasing an additional 1,409,707 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Apellis Pharmaceuticals by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock worth $52,229,000 after purchasing an additional 22,609 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).